Actualités et vidéos - BAVARIAN NORDIC A/S [CBOE] - Page 2

COPENHAGEN, Denmark, January 31, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that Ole Larsen, Executive Vice President and Chief Financial Officer will depart from the Company to pursue new opportunities. The planned transition will take place within 2018 once an appropriate candidate has been identified. Until such time, Mr. Larsen will continue in his current capacity. Mr. Larsen joined Bavarian Nordic in 2008. "On behalf of the entire Company, I want to thank Ole for...

Brachyury plays a key role in metastasis and progression of tumors and is overexpressed in several major, as well as orphan cancers COPENHAGEN, Denmark, January 19, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a clinical trial of BN-Brachyury, a novel cancer immunotherapy candidate designed to target brachyury, a key driver of cancer metastasis in several tumor types. The open-label Phase 1 trial will evaluate the safety and tolerability of the MVA-BN ®...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

COPENHAGEN, Denmark, November 22, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 2,637,500 as a consequence of employees' exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 63,250 shares at DKK 73.90 and 200,500 shares at DKK...

Award of approximately USD 37 million will support clinical work required for product approval COPENHAGEN, Denmark, November 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) have exercised an option under the recently announced contract for freeze-dried IMVAMUNE ® . The option, which represents approximately USD 37 million of the total contract of up to USD 539 million, will cover development costs...

Study to help determine if MVA-BN RSV will be administered as a seasonal vaccine or if a single shot is effective for multiple seasons COPENHAGEN, Denmark, November 9, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that dosing has commenced in the Phase 2 extension study of MVA-BN ® RSV, a universal vaccine candidate designed to elicit a broad antibody and T-cell response against multiple respiratory syncytial virus (RSV) antigens. This study is designed to help determine...

COPENHAGEN, Denmark, November 8, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results in line with guidance for the first nine months of 2017 and business progress for the third quarter of 2017. Third quarter highlights and subsequent events In October, the Canadian Department of National Defence exercised another option for the procurement of 20,000 doses of IMVAMUNE ® smallpox vaccine, and has thereby exercised 80,000 doses to-date of the 180,000...

Initial base award secures additional IMVAMUNE bulk contract of USD 100 million Contract includes initial options valued at USD 439 million Potential for contract value to increase if options to purchase additional IMVAMUNE bulk or freeze dried doses are exercised. Company to host conference call tomorrow at 3:00 pm CEST (09:00 am EDT) COPENHAGEN, Denmark, September 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the award of a sole source contract from the Biomedical...

Preliminary 6 Month Phase 2 Data continue to Demonstrate a Broad and Durable Immune Response against RSV Updated Clinical Plans to Develop and Initiate a Human Challenge Study in 2018 COPENHAGEN, Denmark, September 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced initial 6 month follow-up data from the Phase 2 trial of MVA-BN ® RSV, a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of the respiratory syncytial virus...

Conference call scheduled for 2:00 PM CEST / 8:00 AM EDT tomorrow, Friday, September 15 COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that an independent Data Monitoring Committee (DMCB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 PROSPECT study of PROSTVAC ® in patients with metastatic castration-resistant prostate cancer (mCRPC) is futile. "We are extremely disappointed for patients that this...

COPENHAGEN, Denmark, August 25, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first half of 2017 and releases its financial calendar for 2018. Below is a summary of the financial performance for the period and business progress for the last quarter. The full interim report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com . Recent highlights In July, Bavarian Nordic and Janssen expanded their...

COPENHAGEN, Denmark, August 22, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has received notification from Johnson & Johnson Innovation - JJDC, Inc. (JJDC) pursuant to section 29 of the Danish Securities Trading Act, that JJDC, after the subscription of 512,102 new shares in Bavarian Nordic, has increased its ownership in Bavarian Nordic and now holds 1,844,086 shares in Bavarian Nordic corresponding to 5.77 % of the share capital and voting rights in Bavarian Nordic. JJDC is a...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

COPENHAGEN, Denmark, August 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the closing of the transaction with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson regarding the license and collaboration agreement entered into on July 27, 2017 (see company announcement no. 20/2017 for additional information). The transaction has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act. Consequently, Bavarian Nordic...

COPENHAGEN, Denmark, August 9, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces the subscription price and the number of new shares to be issued to Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in connection with the license and collaboration agreement entered into on July 27, 2017 with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (see company announcements no. 20/2017 and 21/2017 for additional details). The subscription price...

COPENHAGEN, Denmark, July 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces additional details regarding the issue of shares to Johnson & Johnson Innovation - JJDC, Inc. ("J&J") in connection with the agreements entered into today with Janssen, under which the Company has granted Janssen the exclusive rights to Bavarian Nordic's MVA-BN ® technology in two programs focused on hepatitis B (HBV) and human immunodeficiency virus (HIV-1). See company announcement no. 20/2017 for...

Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola Total potential agreement value up to $879 million USD including upfront, equity investment and milestone payments Development efforts will employ both companies' technologies to tackle hepatitis B and human immunodeficiency virus As a consequence of the agreement, the Company raises its expectations for the year-end cash preparedness from approximately DKK 2,400 million to approximately DKK 2,600...

Updated Articles of Association for Bavarian Nordic A/S BavarianNordicArticlesofAssociation This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Globenewswire...

COPENHAGEN, Denmark, July 3, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Board of Directors in Bavarian Nordic A/S has decided to issue warrants to Tommi Kainu, newly appointed Chief Business Officer and member of the executive management. The decision is made in accordance with the shareholder authorization for the board of directors adopted as Article 5b of the Articles of Association and the Company's guidelines regarding incentive remuneration. The Board of...